What are the benefits and harms of bisphosphonates, PTH or PTHrP analogues, denosumab, and romosozumab for preventing fractures in men, based on clinical trials?
Current evidence highlights the benefits of interventions like denosumab and teriparatide in improving BMD and reducing fracture risk in men, although safety profiles, particularly cardiovascular risks with romosozumab, must be carefully managed.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-13
- DOI
- https://doi.org/10.5281/zenodo.24194200
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00